Literature DB >> 28187062

Risk Factors for Growth Retardation in HIV-infected Senegalese Children on Antiretroviral Treatment: The ANRS 12279 MAGGSEN Pediatric Cohort Study.

Cecile Cames1, Lea Pascal, Aminata Diack, Helene Mbodj, Baly Ouattara, Ndeye Rama Diagne, Ndeye Fatou Diallo, Philippe Msellati, Ngagne Mbaye, Haby Sy Signate.   

Abstract

OBJECTIVES: To describe prevalence and risk factors for wasting and stunting among HIV-infected children with a median duration of 3 years of antiretroviral therapy (ART) at the time of their enrollment in the cohort study.
METHODS: Wasting and stunting at ART initiation and enrollment were defined as weight-for-height/body mass index-for-age Z scores < -2 and height-for-age Z scores < -2, respectively. Logistic regression was used to assess risk factors for wasting and stunting. Main predictive factors were age at enrollment, nutritional status and age (< or ≥5 years) at ART initiation and ART duration (< or ≥3 years on first-line, or ≥3 years including a switch to second-line ART).
RESULTS: Two hundred forty-four children 2-16 years of age were enrolled. Overall, wasting and stunting prevalence dropped off consistently in children 2-10 years of age, between ART initiation and enrollment, while it remained at high levels, 52% and 42%, respectively, in children 10-16 years of age. Risk factors for wasting at enrollment were ART duration of ≥3 years including a switch to second-line [adjusted odds ratio (aOR): 3.9, 95% confidence interval (CI): 1.7-8.9] and wasting at ART initiation (aOR: 2.7, 95% CI: 1.4-5.2). The risk factor for stunting at enrollment was stunting at ART initiation (aOR: 11.6, 95% CI: 5.4-25.0), independent of ART duration.
CONCLUSIONS: Malnutrition at the time of ART initiation was the main predictor of malnutrition at enrollment among HIV-infected children on ART. Longer duration on ART had no overall protective effect on wasting and stunting. Growth and virologic monitoring are of utmost importance in the comprehensive care of children with HIV infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28187062     DOI: 10.1097/INF.0000000000001454

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  Growth in the first 5 years after antiretroviral therapy initiation among HIV-infected children in the IeDEA West African Pediatric Cohort.

Authors:  Julie Jesson; Ayoko Ephoevi-Ga; Sophie Desmonde; Marie-Hélène Ake-Assi; Marcelline D'Almeida; Haby Signaté Sy; Karen Malateste; Madeleine Amorissani-Folquet; Fatoumata Dicko; Kouakou Kouadio; Lorna Renner; Valériane Leroy
Journal:  Trop Med Int Health       Date:  2019-04-15       Impact factor: 2.622

Review 2.  Growth and pubertal development in HIV-infected adolescents.

Authors:  Paige L Williams; Julie Jesson
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

3.  Stunting and growth velocity of adolescents with perinatally acquired HIV: differential evolution for males and females. A multiregional analysis from the IeDEA global paediatric collaboration.

Authors:  Julie Jesson; Michael Schomaker; Karen Malasteste; Dewi K Wati; Azar Kariminia; Mariam Sylla; Kouakou Kouadio; Shobna Sawry; Mwangelwa Mubiana-Mbewe; Samuel Ayaya; Rachel Vreeman; Catherine C McGowan; Marcel Yotebieng; Valériane Leroy; Mary-Ann Davies
Journal:  J Int AIDS Soc       Date:  2019-11       Impact factor: 5.396

Review 4.  Under-nutrition and associated factors among children infected with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Jemberu Nigussie; Bekahegn Girma; Alemayehu Molla; Moges Mareg; Esmelealem Mihretu
Journal:  Arch Public Health       Date:  2022-01-05

5.  Growth improvement following antiretroviral therapy initiation in children with perinatally-acquired HIV diagnosed in older childhood in Zimbabwe: a prospective cohort study.

Authors:  Victoria Simms; Grace McHugh; Ethel Dauya; Tsitsi Bandason; Hilda Mujuru; Kusum Nathoo; Shungu Munyati; Helen A Weiss; Rashida A Ferrand
Journal:  BMC Pediatr       Date:  2022-07-25       Impact factor: 2.567

6.  Physical growth and sexual maturation of perinatally HIV-infected adolescent males in a southeast Nigerian tertiary hospital: a comparative cross-sectional study.

Authors:  Chibuzo O Ndiokwelu; Samuel N Uwaezuoke; Kenechukwu K Iloh
Journal:  BMC Pediatr       Date:  2022-10-05       Impact factor: 2.567

7.  Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.

Authors:  Cecile Cames; Lea Pascal; Aissatou Ba; Hélène Mbodj; Baly Ouattara; Ndeye-Fatou Diallo; Philippe Msellati; Ngagne Mbaye; Haby Sy Signate; Stephane Blanche; Aminata Diack
Journal:  BMC Infect Dis       Date:  2018-08-06       Impact factor: 3.090

8.  Adherence to ready-to-use food and acceptability of outpatient nutritional therapy in HIV-infected undernourished Senegalese adolescents: research-based recommendations for routine care.

Authors:  Fatou Niasse; Marie Varloteaux; Karim Diop; Sidy Mokhtar Ndiaye; François Niokhor Diouf; Pape Birane Mbodj; Babacar Niang; Aminata Diack; Cecile Cames
Journal:  BMC Public Health       Date:  2020-05-15       Impact factor: 3.295

9.  Impact of Highly Active Antiretroviral Therapy on Chronic Hepatitis B Serological Markers among Senegalese HIV Co-infected Children.

Authors:  Abou Ba; Fatou K Ndiaye; Yaay J Djeng; Cecile Cames; Aminata Diack; Ousmane N'diaye
Journal:  Int J MCH AIDS       Date:  2019-11-27

10.  Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents.

Authors:  Neil Thivalapill; Tandzile Simelane; Nobuhle Mthethwa; Sandile Dlamini; Bhekumusa Lukhele; Velephi Okello; H Lester Kirchner; Anna M Mandalakas; Alexander W Kay
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.